Background: Previous studies suggest that dexmedetomidine has a protective effect against local anaesthetic-induced nerve injury in regional nerve blocks. Whether this potentially protective effect exists in the context of diabetes mellitus is unknown. Methods: A diabetic state was established in adult male SpragueeDawley rats with intraperitoneal injection of strep-
Ultrasound-guided regional anaesthesia techniques facilitate nerve blocks have gained popularity. The addition of adjuvants such as dexmedetomidine to local anaesthetics (LA) improves the quality and prolongs the duration of the block. 1, 2 The potential neurological toxicity of LAeadjuvant combinations should be ruled out before adopting them into clinical practice.
Most animal studies have not observed long-term neurotoxicity with common peripheral nerve block adjuvants. 3 Dexmedetomidine, an a 2 adrenoceptor agonist, decreases perineural inflammation and attenuates bupivacaine-induced nerve injury in rat sciatic nerve block models. 4e7 However, these studies were carried out in non-diabetic rats. Diabetic individuals undergoing peripheral nerve block might be more sensitive to LA neurotoxicity. One animal study showed that lidocaine 4% induced significantly more oedema in diabetic nerves than in controls. 8 Another study showed that diabetic rats receiving lidocaine 1% plus clonidine 7.5 mg ml À1 or ropivacaine 0.5% alone had more abnormal myelinated axon profiles than non-diabetic rats. 9 Clinical studies have also shown that diabetic neuropathic nerves exhibit complex functional changes and seem to be more sensitive to LA. 10 The neuroprotective effects of dexmedetomidine against LAinduced nerve injury could translate into significant clinical benefit. The aim of the current study was to investigate potential neurotoxicity and underlying mechanisms of perineural ropivacaine and dexmedetomidine alone or in combination in normal or diabetic rats.
Methods

Animals and diabetes mellitus model
Experimental procedures and protocols used in this investigation were approved by the Institutional Animal Care and Use Committee of Peking University Third Hospital, Beijing, China. Male SpragueeDawley rats (Vital River Laboratories, Peking, China) weighing 192e252 g were housed in an animal care facility thermostatically maintained at 20 C with a 12-h lightedark cycle. Diabetic rats were confirmed by blood glucose concentration measurements in samples obtained from the tail vein 3 weeks after injection. Rats whose blood glucose concentration was >350 mg dl À1 were considered to be diabetic. Rats in the control group received vehicle citrate buffer injection.
Verification of diabetic neuropathy
Tactile allodynia in response to electronic von Frey stimulation 12 of hind paw plantar surface was used as the criterion for diabetic neuropathy. 13 The pressure was gradually increased and maintained for 1e2 s until a brisk lifting of the hind paw was considered as a positive response. Each hind paw was assigned six stimulation sites for 30 s intervals. The average of the six stimulation sites was calculated as the withdrawal threshold.
Measurement of the motor nerve conduction velocity
After induction anaesthesia with 3 vol% isoflurane and then maintenance with 1e1.2% isoflurane in oxygen via mask, the left and right hind limbs were shaved. Electrical stimuli were produced using a Cadwell Cascade Elite electrophysiological monitor (Cadwell Co., Kennewick, WA, USA) driven by a 50 ms, 20 mA monophasic stimulus. The active stimulation electrode was inserted first at the ankle and then at the sciatic notch; the stimulation reference electrode was inserted 5 mm proximal to the stimulation electrodes. The record electrode was inserted at the muscle between the first and second plantar pad of the hind limb; the record reference electrode was inserted 5 mm proximal to the record electrodes. 14 To calculate the motor nerve conduction velocity (MNCV), the distance between stimulation sites was divided by the difference in latency to the evoked motor response. Repeated baseline measurements were made at 1 min intervals for 5 min to ensure that the response amplitudes were within ±10% of the average and that the response was not decaying over time.
Sciatic nerve block
Sciatic nerve blockade was performed at the 5th week after induction of diabetes mellitus as described. 15, 16 Animals were briefly anaesthetised with 1.2e1.5 vol% isoflurane in oxygen by mask and placed in the lateral position. The thigh was laterally incised and muscle fascia separated by blunt dissection to expose the sciatic nerve. The experimental drug (0.2 ml) was injected into the perineural space below the clear fascia covering the nerve using a tuberculin syringe with a 30 G needle. Ropivacaine 1% (Naropin; Astra Zeneca PLA, Wuxi, China) and dexmedetomidine 100 mg ml À1 (Aibeining; Jiangsu Hengrui Medicine Co., Ltd, Lianyungang, China) were used to prepare a final concentration of ropivacaine 0.5% and a dose of dexmedetomidine 20 mg kg À1 (alone or in combination). Drugs were diluted with normal saline to 0.2 ml. Except for the naive controls treated with saline (n¼4), rats treated with ropivacaine and dexmedetomidine alone or in combination were randomly assigned. For each set of experiments, eight control rats and eight diabetic rats received blocks on both sides. S, R, D, RD represented control rats receiving saline, ropivacaine, dexmedetomidine, or ropivacaine with dexmedetomidine, whereas S-DM, R-DM, D-DM, RD-DM represented diabetic rats receiving saline, ropivacaine, dexmedetomidine, or ropivacaine with dexmedetomidine, respectively. After recovery from general anaesthesia, a sensory response was evaluated by observing foot withdrawal when a pin was applied to the plantar midline surface of each hind paw (tibial nerve distribution). 4, 17 Motor response was evaluated by observing the toe spreading reflex (peroneal nerve
Editor's key points
Dexmedetomidine is used as an adjuvant to prolong the duration of peripheral nerve block, but its impact on possible local anaesthetic nerve toxicity is not known, particularly with co-existing diabetes mellitus. Dexmedetomidine alone did not exhibit neurotoxicity, but it significantly enhanced both the duration of nerve blockade and nerve toxicity produced by ropivacaine in a rat model of diabetes mellitus. Further studies are indicated to determine the mechanism and clinical relevance of this observation to patients with diabetes mellitus or other causes of peripheral neuropathy that might predispose to toxicity.
motor fibres), which is a vestibular reflex induced by lifting the rat and producing a response with the toes extended and spread. 9, 13, 18 For both tests, responses were rated as present or absent. Sensory and motor blockade were tested every 30 min until full recovery.
Histomorphometry and determination of proinflammatory cytokine concentration
Seven days after sciatic nerve block, rats were anaesthetised with 1.2 vol% isoflurane in oxygen by mask, and MNCV was measured as described above. The sciatic nerve was gently exposed over a length of 20 mm from the sciatic notch to the mid-thigh, 9,13 and the nerve was harvested after euthanasia with an overdose of pentobarbital (120 mg kg À1 , i.p.). Left limb nerve samples were homogenised in protease inhibitor cocktail (Pplygen) and centrifuged at 1,000g of 3000 rpm for the machine used. The supernatant was used to measure interleukin (IL)-1b and tumour necrosis factor (TNF)-a using custom enzyme-linked immunosorbent assay (ELISA) kits (Abcam, Cambridge, UK). Right limb nerve samples were stained with toluidine blue to determine the number of differently sized axons 19 and the G ratio in each section. 20, 21 G ratio is the ratio of the inner to outer diameter of the myelin sheath, and was used to assess axonal myelination. Ten field micrographs of one section of each rat were obtained under 100Â magnification, and the mean G ratio of those 10 fields calculated for further statistical analysis. The remaining limb tissue samples of all rats (n¼4 in the naïve control treated with saline and n¼8 in all other groups) were placed in 3% electron microscopy grade glutaraldehyde solution at 4 C. Electron microscopy was performed to assess axonal degeneration and demyelination with image analysis performed by a histologist blinded to the experimental groups.
Statistical analysis
Normal distribution of data was tested with the ShapiroeWilk test. Normally distributed data were expressed as mean (standard deviation, SD), whereas non-parametric data were expressed as median (range). Normally distributed data were analysed with analysis of variance (ANOVA) followed by NewmaneKeuls post hoc test. Non-parametric data were analysed using ANOVA 
Duration of sciatic nerve block
Animals had sensory and motor nerve block lasting for >100 min after sciatic nerve block with ropivacaine 0.5% (dexmedetomidine alone and saline did not produce nerve block). Ropivacaine, with or without dexmedetomidine, produced longer mean duration of sensory nerve block in diabetic rats than controls. Sensory and motor block with ropivacaine 0.5% lasted 2.0 (1.8e2.1) h in controls, but this was extended by 2 h in diabetic animals (P<0.05). The addition of dexmedetomidine to ropivacaine produced a small but significant increase in sensory and motor block in controls, but extended sensory and motor block in diabetic rats by more than 60 h ( Fig. 1 ; median and range of these data are shown in Supplementary Table S1 ).
Motor nerve conduction velocity
Before sciatic nerve block, rats in the control group had a mean MNCV of 41.1 (5.5) m s À1 , whereas those in the diabetic group had a mean MNCV of 33.3 (4.5) m s À1 (P<0.05). With the exception of the RD-DM group, the MNCV tested at 1 week after the procedure returned to baseline (Fig. 2) . 
Pro-inflammatory cytokines
One week after sciatic nerve block, nerve tissue in all in control rats showed no significant difference in the amounts of IL-1b and TNF-a ( Fig. 3a and d) . There was also no significant difference in cytokine levels in the nerves from rats treated with saline, dexmedetomidine, or ropivacaine in diabetic rats (P>0.05). Nerves in the ropivacaine plus dexmedetomidine group had higher levels of these two pro-inflammatory cytokines compared with saline, dexmedetomidine, and ropivacaine group in diabetic rats (P<0.05; Fig. 3b and e) . Moreover, nerves in the ropivacaine plus dexmedetomidine group had higher levels of these two pro-inflammatory cytokines compared with the ropivacaine group of diabetic rats (P<0.05; Fig. 3c and f) .
Histology
In the control groups, there was no significant difference in the number of axons per field 1 week after sham nerve block (axon density; Fig. 4a and b) . Axon density was significantly decreased in diabetic rats blocked with ropivacaine plus dexmedetomidine, but there was no significant difference in the other three groups (Fig. 4c) . Compared with control groups, axon density was significantly decreased in diabetic rats with ropivacaine injection (Fig. 4d) . The G ratio of axons was lower in diabetic rats compared with controls for each diameter, and nerve block with ropivacaine plus dexmedetomidine yielded a lower G ratio for diameters of 2e3, 3e4, and 4e5 mm than ropivacaine alone in the diabetic rats (Fig. 5 ).
Electron microscopy
Segmental demyelination and degeneration of axonal fibres was found in all treatment groups. In all diabetic rats, there were larger areas of demyelination and degeneration of axons.
These changes were more pronounced in the ropivacaine groups (R-DM and RD-DM); the most severe damage was seen in the RD-DM group with full-thickness demyelination and vacuole formation (Fig. 6 ). The severe nerve damage induced by ropivacaine and dexmedetomidine alone or in combination shown was confirmed by our colleagues (Y.B. Sun, D.X. Wang, and S.L. Wang; Peking University) as an independent group. Using the identical experimental protocol, similar results were found (Supplementary Tables S2 and S3 , and Figs S1 and S2).
Discussion
Previous studies have shown that addition of dexmedetomidine to perineural LA alleviates oxidative stress and reduces peripheral nerve injury in non-diabetic models. 5e7 Our aim was to verify that dexmedetomidine attenuates ropivacaineinduced neurotoxicity in a streptozotocin model of diabetes mellitus. However, although dexmedetomidine itself did not cause sciatic nerve injury in diabetic rats, it drastically enhanced the nerve injury induced by ropivacaine with more significant histopathological changes and greater proinflammatory cytokine levels.
In line with previous studies, 9, 13, 18 our data show that ropivacaine 0.5% alone injected into the sciatic notch produces longer sensory and motor blockade in diabetic rats compared with non-diabetic rats. We also showed that dexmedetomidine added to ropivacaine significantly enhanced sensory and motor blockade of the sciatic nerve and prolonged the duration of block in all rats; these changes were significantly more pronounced in diabetic rats. Dexmedetomidine alone did not produce nerve blockade, as reported previously. 4, 16, 22 The median and range of duration of both sensory and motor block in the R, RD, and R-DM groups in our current study were of a similar order of magnitude to those reported in studies where equivalent doses of ropivacaine and dexmedetomidine were used. Any variability is likely to reflect differences in methodology in assessing block duration between studies. A summary of relevant previous studies is shown in Supplementary  Table S4 for comparison. Pre-existing neuropathy (such as in diabetes mellitus) as a possible risk factor for LA-induced nerve injury has been described. 8,9,13,23e25 However, this is the first study to describe the profound enhancement of block duration and significant neurotoxicity-enhancing effects of dexmedetomidine when added to perineural ropivacaine in a diabetes model. The mechanisms of action underlying these observations have not yet been identified. The large increase in the duration of nerve block in diabetic rats is likely caused by metabolic factors. 9, 13 Streptozotocin-induced diabetic rats have altered neural protein kinase C activity 26 and altered potassium and sodium conductance leading to decreased hyperpolarizationactivated cation current (I h ) in large sensory axons 27 that may contribute. It has been shown that dexmedetomidine enhances LA action via peripheral a 2A adrenoceptor agonism, 28 and increases the duration of analgesia by inhibition of I h by a mechanism independent of the a 2A receptor. 16 This double inhibition of I h might explain the large increase in block duration (by >60 h) in the RD-DM group. 16, 28 A previous study reported a correlation between block duration and nerve fibre damage in diabetic rats 13 although a causative link has not been established, and our findings support that observation. Ropivacaine plus dexmedetomidine produced severe demyelination and degeneration of axons in diabetic rats. We Motor nerve conduction velocity at baseline and 1 week after block. Motor nerve conduction velocity (MNCV) at 1 week after block was significantly different from baseline measurements in the DR-DM group only (*P<0.01). #MNCV was significantly different from RD-DM at 1 week after block (P<0.05). D, dexmedetomidine in normal rats; D-DM, dexmedetomidine in in diabetic rats; R, ropivacaine in normal rats; RD, ropivacaine plus dexmedetomidine in normal rats; R-DM, ropivacaine in diabetic rats; RD-DM, ropivacaine plus dexmedetomidine in diabetic rats. Data shown are mean (standard deviation, SD) (n¼4 in the naive control and n¼8 in other groups).
speculate that the pre-existing neuropathy induced by diabetes, with complex functional changes such as altered ionic currents 29 and aberrant calcium homeostasis 30 explains this.
Inflammation also clearly plays a role as evidenced by the increase in pro-inflammatory cytokines in the RD-DM group. Another possibility is that the higher dose of dexmedetomidine used in our study causes a 2 receptor-mediated vasoconstriction with reduced perineural blood flow that potentiates TNF-a and IL-1b in sciatic nerves. Levels of pro-inflammatory cytokines measured 1 week after sciatic nerve block by ELISA. Data shown are mean (standard deviation, SD) (n¼4 in the naive control and n¼8 in other groups), (*P<0.05, **P<0.01). D, dexmedetomidine in normal rats; D-DM, dexmedetomidine in in diabetic rats; ELISA, custom enzyme-linked immunosorbent assay TNF-a, tumour necrosis factor-alpha; IL-1b, interleukin 1beta; R, ropivacaine in normal rats; R-DM, ropivacaine in diabetic rats; RD, ropivacaine plus dexmedetomidine in normal rats; RD-DM, ropivacaine plus dexmedetomidine in diabetic rats; S, saline in normal rats; S-DM, saline in diabetic rats.
ropivacaine-induced neurotoxicity. a 2 receptor-independent upregulation of norepinephrine release by high-dose dexmedetomidine may also contribute. 31 We observed neither an increase in perineural inflammation with LA treatment in non-diabetic rats nor a significant reduction in perineural inflammation with dexmedetomidine addition in non-diabetic rats, as has been reported. 4, 5 Previous studies also found that perineural administration of dexmedetomidine 20 mg kg À1 reduced sciatic nerve levels of IL-6 and TNF-a at both the mRNA and protein levels. 6 The different time points at which the tissue samples were harvested are likely to explain this (7 days after injection in our study vs between 24 h and 14 days in previous work; see Supplementary Table S4 ). Brummett and colleagues 4 showed that these anti-inflammatory effects of dexmedetomidine were only evident at 24 h and that there was no significant difference in inflammation between groups at 14 days; this fits with our results and suggests an acute anti-inflammatory effect only in non-diabetic rats. Furthermore, when dexmedetomidine was administered systemically it increased pain threshold, suppressed microglia activation, and decreased pro-inflammatory cytokines in the spinal cord in streptozotocin-induced diabetic rats. 32 This finding of a protective rather detrimental effect with systemic dexmedetomidine is consistent with protective effects afforded by intravenous infusion of dexmedetomidine. 33 The dose of dexmedetomidine used in our study is much higher than that being used clinically. Because of interspecies variability and fundamental differences between human and animal models of disease, drug doses that need to be used in animal models are often much higher than those used clinically (often up to 10-fold higher). The literature on translating doses from animal models to human trials has repeatedly shown that it is far more complex than scaling dosage based on body mass. 34, 35 Therefore, it is invalid to assume that a 20 mg kg À1 dose of dexmedetomidine in a rodent is equivalent to a 20 mg kg À1 dose in a human. Our choice of dose was determined by those used in a number of studies conducted previously to allow for comparison with the established literature (Supplementary Table S4) . Moreover, the same dose used in normal controls did not cause any damage, indicating its inherent neurotoxic effect in the diabetic condition. An open wound model was used in the present study to avoid unintentional intra-nerve injection, but the potential impact of local tissue damage on inflammatory state in those animals cannot be ruled out. However, cytokines were not significantly increased in sham surgery controls, suggesting again that the disease conditions rather than other factors resulted in the toxic effects of the treatments. The streptozotocin-induced diabetes model is not an ideal model to mimic the human neuropathy 2 of type 2 diabetes mellitus, so one should consider this in interpreting our data. Lastly, whether a 2 adrenoceptors are involved in dexmedetomidine-induced neurotoxicity is not unknown; if nerve fibre damage already exists in the diabetic condition, introducing another chemical of a 2 adrenoceptor antagonist may cause further nerve damage rather than reduce the toxicity. In summary, high-dose perineural dexmedetomidine enhanced LA-induced nerve injury in a rat diabetes model. Because of these unexpected findings, further study is necessary to investigate the effects of clinically relevant doses of dexmedetomidine in a model of type 2 diabetes mellitus and its mechanisms. It is premature to extrapolate the present results to clinical recommendations about the risks and benefits of this adjuvant to LA when performing regional anaesthesia in patients with pre-existing neuropathy. Establishing a doseeresponse relationship for these observations and further work looking at the underlying mechanisms will help clarify these important questions. The mean G ratio of those 10 fields was calculated for further analysis and expressed as mean (standard deviation, SD) (n¼4 in the naive control and n¼8 in other groups); *P<0.05. D-DM, dexmedetomidine in in diabetic rats; R-DM, ropivacaine in diabetic rats; RD-DM, ropivacaine plus dexmedetomidine in diabetic rats; S-DM, saline in diabetic rats.
